Latest Tibolone Stories
Researchers say they have found the first robust evidence that low doses of a hormone called DHEA can help sexual function and menopausal symptoms.
New research presented this week highlights the ability of NextBio to help life scientists and clinicians investigate publicly available genomic data to assess biological mechanisms underlying drug toxicity, as well as discover prospective cancer biomarkers for further validation.
Elsevier announced today the publication of four important position statements from the European Menopause and Andropause Society (EMAS) in the journal Maturitas (http://www.maturitas.org/) on common management problems in the post-reproductive health of women.
Although tamoxifen, raloxifen and tibolone dramatically reduce the risk of invasive breast cancer, some patients experience adverse effects.
ROCKVILLE, Md., Sept.
Drugs used to lower the risk of breast cancer in women have the side effect of increasing the likelihood of blood clots, researchers in Oregon say. The study, published in the current issue of Annals of Internal Medicine, examined the effects of tamoxifen, raloxifene and tibolone reduce the risk of invasive breast cancer by 30 percent to 68 percent.
A large study of tibolone, a synthetic steroid used to treat menopausal symptoms and to prevent osteoporosis, was stopped six months early after researchers found that the drug substantially increased the risk of a relapse in breast cancer patients.
- totally perplexed and mixed up.